Estrella Immunopharma Inc (ESLA) FinancialsESLAEstrella Immunopharma Inc

In the context of the broader market, ESLA competes directly with industry leaders such as LGVN and IGC. With a market capitalization of $31.46M, it holds a significant position in the sector. When comparing efficiency, ESLA's gross margin of N/A stands against LGVN's 63.41% and IGC's 18.11%. Such benchmarking helps identify whether Estrella Immunopharma Inc is trading at a premium or discount relative to its financial performance.

Estrella Immunopharma has shown significant losses, with a net income of -2,306,339 USD in Q2 2026 and a current ratio of 0.20, indicating liquidity issues. The company has a negative price-to-book ratio of -4.225501, suggesting that the stock is trading below its book value, which is a red flag for investors.